A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants
2026年9月4日 更新者：Jazz Pharmaceuticals
A Phase 1, Randomized, Double-Blind, Sponsor-Unblinded, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants
This study will characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of JZP269 in healthy participants.
調査の概要
詳細な説明
This first-in-human study is designed to characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of JZP269, an orexin-2 receptor agonist, in healthy participants.
The study will also assess the effect of food on JZP269 PK, characterize cerebrospinal fluid (CSF) exposure, and evaluate the wake-promoting PD effects using the Maintenance of Wakefulness Test (MWT) and Karolinska Sleepiness Scale (KSS) in sleep-deprived participants.
研究の種類
介入
入学 (推定)
188
段階
- フェーズ 1
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前：Clinical Trial Disclosure & Transparency
- 電話番号：215-832-3750
- メール：ClinicalTrialDisclosure@JazzPharma.com
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
はい
説明
Participants are eligible to be included in the study only if all of the following criteria apply:
- Is 18 to 55 years of age, inclusive, at the time of signing the informed consent.
- Is overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac/blood pressure monitoring.
- Has a body weight of at least 45 kg and BMI within the range of 18.5 to 30 kg/m^2 (inclusive).
Participants are excluded from the study if any of the following criteria apply:
- Has a history of or presence of clinically significant medical illness as specified in the protocol.
- Has a family history (first degree relative) of torsades de pointes, premature sudden death, long QT syndrome, or clinically significant cardiac conduction disorders.
- Has a known or suspected history of schizophrenia or other psychotic illness or a history of severe personality disorder or other significant psychiatric disorder.
- Has a history (within 5 past years) or presence of diagnosis of alcohol abuse or alcohol use disorder, substance abuse or substance use disorder, or known drug dependence or is seeking treatment for an alcohol or substance abuse related disorder.
- Has a current diagnosis of or is receiving treatment for depression or has a history (within past 5 years) of clinically significant major depressive episode.
- Has a history of suicide attempt, a current suicidal risk as determined from history, or the presence of active suicidal ideation as indicated by a positive response to Item 4 or Item 5 on the C-SSRS (within the past 24 months).
- In participants where cerebrospinal fluid will be collected, any contraindications to lumbar puncture including increased intracranial pressure, conditions that may lead to brain herniation, a history of degenerative spine disease or lumbar spinal stenosis, a history of lumbar surgery, or prior history of adverse experience with lumbar puncture (eg, headache).
- Has a clinically significant ECG abnormality per investigator assessment or an average PR > 200 msec, average QRS > 110 msec, average QTcF > 440 msec for men and women, or flattened or difficult to distinguish T-waves.
- Has a resting supine systolic blood pressure > 140 mmHg or < 90 mmHg, resting supine diastolic blood pressure > 90 mmHg or < 50 mmHg, or resting supine heart rate > 100 bpm or < 40 bpm at screening or check-in.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：JZP269
Participants will receive JZP269.
|
Administered as described.
|
|
プラセボコンパレーター：Placebo
Participants will receive a matching placebo.
|
Administered as described.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants Reporting Treatment-emergent Adverse Events
時間枠：Day 1 of dosing and monitoring period up to 7 days after last dose (Safety Follow Up Visit)
|
Day 1 of dosing and monitoring period up to 7 days after last dose (Safety Follow Up Visit)
|
|
|
Pharmacokinetic Parameter Maximum Concentration (Cmax) of JZP269
時間枠：Predose up to 48 hours postdose
|
Predose up to 48 hours postdose
|
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) of JZP269
時間枠：Predose up to 48 hours postdose
|
Predose up to 48 hours postdose
|
|
|
Pharmacokinetic Parameter Apparent Terminal Elimination Half-life (t1/2) of JZP269
時間枠：Predose up to 48 hours postdose
|
Predose up to 48 hours postdose
|
|
|
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP269
時間枠：Predose up to 48 hours postdose
|
Area under the concentration-time curve from time 0 to 24 hours (AUC0-24), area under the concentration time curve from time 0 to the last measurable concentration (AUC0-last), and area under the concentration-time curve from time 0 to infinity will be assessed (AUC∞).
|
Predose up to 48 hours postdose
|
|
Pharmacokinetic Parameter Oral Clearance (CL/F) of JZP269
時間枠：Predose up to 48 hours postdose
|
Predose up to 48 hours postdose
|
|
|
Pharmacokinetic Parameter Apparent Volume of Distribution During the Terminal Phase (Vz/F) of JZP269
時間枠：Predose up to 48 hours postdose
|
Predose up to 48 hours postdose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dose Proportionality of JZP269 Area Under the Concentration-Time Curve (AUC)
時間枠：Predose up to 48 hours postdose
|
Dose proportionality of JZP269 AUC0-last, AUC∞, and AUC0-24 will be assessed.
|
Predose up to 48 hours postdose
|
|
Dose Proportionality of JZP269 Maximum Concentration (Cmax)
時間枠：Predose up to 48 hours postdose
|
Predose up to 48 hours postdose
|
|
|
The Effect of Food on the PK of JZP269 Cmax
時間枠：Predose up to 48 hours postdose
|
The effect of food on the PK of JZP269 relative to that observed in the fasted state will be assessed.
|
Predose up to 48 hours postdose
|
|
The Effect of Food on the PK of JZP269 Tmax
時間枠：Predose up to 48 hours postdose
|
The effect of food on the PK of JZP269 relative to that observed in the fasted state will be assessed.
|
Predose up to 48 hours postdose
|
|
The Effect of Food on the PK of JZP269 t1/2
時間枠：Predose up to 48 hours postdose
|
The effect of food on the PK of JZP269 relative to that observed in the fasted state will be assessed.
|
Predose up to 48 hours postdose
|
|
The Effect of Food on the PK of JZP269 AUC
時間枠：Predose up to 48 hours postdose
|
The effect of food on the PK of JZP269 relative to that observed in the fasted state will be assessed.
|
Predose up to 48 hours postdose
|
|
Mean Concentrations of JZP269 in Cerebrospinal Fluid
時間枠：Predose up to 48 hours postdose
|
Predose up to 48 hours postdose
|
|
|
Mean Sleep Latency on the Maintenance of Wakefulness Test (MWT) in Sleep-deprived Participants
時間枠：Day 1 of dosing and monitoring period
|
The MWT measures a participant's ability to remain awake under quiet conditions during the day.
Sleep latency is the time it takes for a participant to fall asleep while trying to remain awake during the MWT, and sleep onset is determined objectively by electroencephalography.
The MWT calculates mean sleep latency as the average time to sleep onset.
Shorter mean sleep latency indicates a greater difficulty maintaining wakefulness.
|
Day 1 of dosing and monitoring period
|
|
Mean Karolinska Sleepiness Scale (KSS) Score in Sleep-deprived Participants
時間枠：Day 1 of dosing and monitoring period
|
The KSS is a 9-point scale that measures subjective sleepiness during the preceding 10 minutes, ranging from 1 ("extremely alert") to 9 ("very sleepy, great effort to keep awake, fighting sleep").
Higher scores indicate greater sleepiness.
|
Day 1 of dosing and monitoring period
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年9月22日
一次修了 (推定)
2027年2月27日
研究の完了 (推定)
2027年2月27日
試験登録日
最初に提出
2026年9月4日
QC基準を満たした最初の提出物
2026年9月4日
最初の投稿 (実際)
2026年9月10日
学習記録の更新
投稿された最後の更新 (実際)
2026年9月10日
QC基準を満たした最後の更新が送信されました
2026年9月4日
最終確認日
2026年9月1日
詳しくは
本研究に関する用語
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request.
Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/
as outlined.
Jazz Pharmaceuticals reserves the right not to consider a request.
For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
はい
米国FDA規制機器製品の研究
いいえ
米国で製造され、米国から輸出された製品。
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。